Watch out, Bristol Myers — J&J is right behind you; Blake Byers leaps out from GV to do his own thing

05 Apr 2021

We’ve learned that J&J has now finished its rolling application for the BCMA-targeted cilta-cel, which one analyst believes will put them about 8 or 9 months behind Bristol Myers Squibb and their partners at bluebird, which just won a delayed OK at the FDA for ide-cel. Legend included word of the wrap-up during Q1 in its 20F filing with the FDA, and analysts were quick to conclude that should allow for an approval by the end of this year.

Organizations

Bristol Myers Squibb Co.

Medifron DBT Co., Ltd.

Indications

Targets

Drugs

Ciltacabtagene autoleucelIdecabtagene Vicleucel

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.